Masimo SG&A Expenses 2010-2024 | MASI

Masimo sg&a expenses for the twelve months ending September 30, 2024 were $0.682B, a 1.1% decline year-over-year.

  • Masimo annual sg&a expenses for 2023 were $0.664B, a 1% increase from 2022.
  • Masimo annual sg&a expenses for 2022 were $0.657B, a 66.26% increase from 2021.
  • Masimo annual sg&a expenses for 2021 were $0.395B, a 7.15% increase from 2020.

Masimo SG&A Expenses 2010-2024 | MASI

  • Masimo annual sg&a expenses for 2023 were $0.664B, a 1% increase from 2022.
  • Masimo annual sg&a expenses for 2022 were $0.657B, a 66.26% increase from 2021.
  • Masimo annual sg&a expenses for 2021 were $0.395B, a 7.15% increase from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$194.7B
Intuitive Surgical (ISRG)$191.9B
Alcon (ALC)$42.1B
Edwards Lifesciences (EW)$41.4B
IQVIA Holdings (IQV)$34.7B
IDEXX Laboratories (IDXX)$34.1B
DexCom (DXCM)$29.2B
STERIS (STE)$20.9B
Waters (WAT)$20.5B
SONOVA HOLDING (SONVY)$20.3B
Hologic (HOLX)$18.2B
Fresenius Medical Care AG KGaA (FMS)$13B
Sysmex ADR (SSMXY)$12.7B
Globus Medical (GMED)$11.3B
Penumbra (PEN)$9.1B
Teleflex (TFX)$9B
Glaukos (GKOS)$8B
PROCEPT BioRobotics (PRCT)$4.9B
Integer Holdings (ITGR)$4.5B
Veracyte (VCYT)$3B
Inari Medical (NARI)$3B
LivaNova (LIVN)$2.8B
TransMedics (TMDX)$2.8B
Nihon Kohden (NHNKY)$2.3B
Elekta AB (EKTAY)$2.2B
Tandem Diabetes Care (TNDM)$1.8B
RxSight (RXST)$1.8B
Integra LifeSciences Holdings (IART)$1.8B
Alphatec Holdings (ATEC)$1.4B
Artivion (AORT)$1.1B